RT Journal
A1 Friedrich MJ
T1 CHoosing diabetes drugs
JF JAMA
JO JAMA
YR 2011
FD May 18
VO 305
IS 19
SP 1953
OP 1953
DO 10.1001/jama.2011.636
UL http://dx.doi.org/10.1001/jama.2011.636
AB 
The study included all Danish residents older than 20 years who had begun taking either single-agent insulin secretagogues (ISs) or metformin between 1997 and 2006—a total of 107 806 people—who were observed for up to 9 years. Compared with metformin treatment, monotherapy with most ISs was associated with a greater risk of death from any cause as well as a greater risk of myocardial infarction, stroke, or death from cardiovascular disease. The ISs gliclazide and repaglinide seem to be associated with a lower risk than the other ISs.